ITTO20080204A1 - Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a - Google Patents

Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a

Info

Publication number
ITTO20080204A1
ITTO20080204A1 IT000204A ITTO20080204A ITTO20080204A1 IT TO20080204 A1 ITTO20080204 A1 IT TO20080204A1 IT 000204 A IT000204 A IT 000204A IT TO20080204 A ITTO20080204 A IT TO20080204A IT TO20080204 A1 ITTO20080204 A1 IT TO20080204A1
Authority
IT
Italy
Prior art keywords
subtips
influential
virus
actions
react
Prior art date
Application number
IT000204A
Other languages
English (en)
Inventor
Roberto Burioni
Massimo Clementi
Original Assignee
Pomona Biotechnologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40293277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITTO20080204(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pomona Biotechnologies Llc filed Critical Pomona Biotechnologies Llc
Priority to IT000204A priority Critical patent/ITTO20080204A1/it
Priority to CA2718923A priority patent/CA2718923C/en
Priority to HUE09722394A priority patent/HUE025329T2/en
Priority to PL09722394T priority patent/PL2274335T3/pl
Priority to JP2011500336A priority patent/JP5542118B2/ja
Priority to PT97223945T priority patent/PT2274335E/pt
Priority to MX2010010120A priority patent/MX2010010120A/es
Priority to KR1020107023021A priority patent/KR101605573B1/ko
Priority to US12/922,850 priority patent/US9200063B2/en
Priority to DK09722394.5T priority patent/DK2274335T3/en
Priority to SG2013018270A priority patent/SG188890A1/en
Priority to BRPI0909123A priority patent/BRPI0909123B8/pt
Priority to EP09722394.5A priority patent/EP2274335B2/en
Priority to CN200980117842.2A priority patent/CN102037013B/zh
Priority to EA201071087A priority patent/EA027069B1/ru
Priority to PCT/IB2009/051068 priority patent/WO2009115972A1/en
Priority to MYPI2010004341A priority patent/MY157359A/en
Priority to AU2009227567A priority patent/AU2009227567B2/en
Priority to NZ588238A priority patent/NZ588238A/xx
Priority to ES09722394T priority patent/ES2544968T5/es
Publication of ITTO20080204A1 publication Critical patent/ITTO20080204A1/it
Priority to ZA2010/06934A priority patent/ZA201006934B/en
Priority to IL208210A priority patent/IL208210A0/en
Priority to US14/938,101 priority patent/US9587011B2/en
Priority to US15/083,584 priority patent/US9598482B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
IT000204A 2008-03-17 2008-03-17 Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a ITTO20080204A1 (it)

Priority Applications (24)

Application Number Priority Date Filing Date Title
IT000204A ITTO20080204A1 (it) 2008-03-17 2008-03-17 Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ES09722394T ES2544968T5 (es) 2008-03-17 2009-03-16 Anticuerpos monoclonales capaces de reaccionar con una pluralidad de subtipos del virus de la influenza A
SG2013018270A SG188890A1 (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
EP09722394.5A EP2274335B2 (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
PL09722394T PL2274335T3 (pl) 2008-03-17 2009-03-16 Przeciwciała monoklonalne zdolne do reagowania z wieloma podtypami wirusa grupy typu A
JP2011500336A JP5542118B2 (ja) 2008-03-17 2009-03-16 インフルエンザａ型ウイルスの複数のサブタイプと反応することができるモノクローナル抗体
PT97223945T PT2274335E (pt) 2008-03-17 2009-03-16 Anticorpos monoclonais capazes de reagirem com diversos subtipos de vírus a da gripe
MX2010010120A MX2010010120A (es) 2008-03-17 2009-03-16 Anticuerpos monoclonales capaces de reaccionar con una pluralidad de subtipos del virus de la influenza a.
KR1020107023021A KR101605573B1 (ko) 2008-03-17 2009-03-16 복수의 인플루엔자 바이러스 ａ 서브타입들과 반응할 수 있는 모노클로날 항체
US12/922,850 US9200063B2 (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
DK09722394.5T DK2274335T3 (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a large number of influenza virus A subtypes
CA2718923A CA2718923C (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
BRPI0909123A BRPI0909123B8 (pt) 2008-03-17 2009-03-16 anticorpos monoclonais, vetor de expressão, célula hospedeira, composição farmacêutica, uso do referido anticorpo, kit de diagnóstico e métodos de ensaio para detectar a presença de epítopos de vírus de influenza a
HUE09722394A HUE025329T2 (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of responding to more than one influenza A subtype
CN200980117842.2A CN102037013B (zh) 2008-03-17 2009-03-16 能与复数个甲型流感病毒亚型反应的单克隆抗体
EA201071087A EA027069B1 (ru) 2008-03-17 2009-03-16 Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
PCT/IB2009/051068 WO2009115972A1 (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
MYPI2010004341A MY157359A (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
AU2009227567A AU2009227567B2 (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
NZ588238A NZ588238A (en) 2008-03-17 2009-03-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
ZA2010/06934A ZA201006934B (en) 2008-03-17 2010-08-29 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
IL208210A IL208210A0 (en) 2008-03-17 2010-09-16 Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
US14/938,101 US9587011B2 (en) 2008-03-17 2015-11-11 Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
US15/083,584 US9598482B2 (en) 2008-03-17 2016-03-29 Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000204A ITTO20080204A1 (it) 2008-03-17 2008-03-17 Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a

Publications (1)

Publication Number Publication Date
ITTO20080204A1 true ITTO20080204A1 (it) 2009-09-18

Family

ID=40293277

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000204A ITTO20080204A1 (it) 2008-03-17 2008-03-17 Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a

Country Status (22)

Country Link
US (3) US9200063B2 (it)
EP (1) EP2274335B2 (it)
JP (1) JP5542118B2 (it)
KR (1) KR101605573B1 (it)
CN (1) CN102037013B (it)
AU (1) AU2009227567B2 (it)
BR (1) BRPI0909123B8 (it)
CA (1) CA2718923C (it)
DK (1) DK2274335T3 (it)
EA (1) EA027069B1 (it)
ES (1) ES2544968T5 (it)
HU (1) HUE025329T2 (it)
IL (1) IL208210A0 (it)
IT (1) ITTO20080204A1 (it)
MX (1) MX2010010120A (it)
MY (1) MY157359A (it)
NZ (1) NZ588238A (it)
PL (1) PL2274335T3 (it)
PT (1) PT2274335E (it)
SG (1) SG188890A1 (it)
WO (1) WO2009115972A1 (it)
ZA (1) ZA201006934B (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294084B1 (en) 2008-05-27 2015-09-09 Pomona Ricerca S.r.l. Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
WO2009079259A2 (en) 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
AU2009275226B2 (en) 2008-07-25 2015-05-14 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
JP5813629B2 (ja) 2009-05-11 2015-11-17 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ３ｎ２を中和可能なヒト抗体及び／または抗原結合フラグメントおよびその使用
IT1395961B1 (it) * 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
WO2011044570A2 (en) * 2009-10-09 2011-04-14 Emory University Recombinant antibodies against h1n1 influenza
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
ITTO20110067A1 (it) * 2011-01-26 2012-07-27 Pomona Ricerca Srl Immunoglobuline intere di isotipo igg atte a riconoscere un epitopo di neutralizzazione eterosubtipica sulla regione stelo (stem region) dell'emoagglutinina e loro uso come medicamento antinfluenzale
EA029198B1 (ru) * 2010-03-26 2018-02-28 Помона Ричерка С.Р.Л. Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа
ITTO20100237A1 (it) * 2010-03-26 2011-09-27 Pomona Biotechnologies Llc Immunoglobuline intere della classe delle igg per l'uso come medicamento antinfluenzale
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
CN102775469B (zh) * 2011-05-12 2018-02-09 厦门大学 甲型流感病毒核衣壳蛋白的抗原表位及其用途
LT3418300T (lt) 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
CN116162175A (zh) 2011-09-20 2023-05-26 西奈山伊坎医学院 流感病毒疫苗及其应用
WO2013059524A2 (en) 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
PH12019501031A1 (en) 2012-11-13 2022-11-14 Genentech Inc Anti-hemagglutinin antibodies and methods of use
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
UA123986C2 (uk) 2014-05-13 2021-07-07 Дзе Трастіз Оф Дзе Юніверсіті Оф Пенсильванія Композиція, яка містить aav, який експресує конструкцію антитіл з подвійною специфічністю, і її застосування
RU2711932C2 (ru) 2014-07-15 2020-01-23 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа B и пути их применения
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
MA48852A (fr) 2015-05-13 2020-04-01 Univ Pennsylvania Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
JP6867306B2 (ja) 2015-06-01 2021-04-28 メディミューン，エルエルシー 中和抗インフルエンザ結合分子及びその使用
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc Method of treating influenza a
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
WO2018160573A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
HRP20240257T1 (hr) 2017-02-28 2024-05-24 The Trustees Of The University Of Pennsylvania Adeno-povezani virusni (aav) clade f vektor i njegova uporaba
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
WO2019241184A1 (en) * 2018-06-11 2019-12-19 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Antibody pairs for use in a rapid influenza a diagnostic test
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
KR20200060969A (ko) 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
WO2020198329A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20240024507A1 (en) 2020-12-01 2024-01-25 The Trustees Of The University Of Pennsylvania Novel compositions with tissue-specific targeting motifs and compositions containing same
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
CN115724952B (zh) * 2022-07-13 2023-10-31 扬州大学 一种靶向甲型流感病毒保守线性b细胞表位的广谱单克隆抗体及其应用
EP4450510A1 (en) * 2023-04-20 2024-10-23 Novaled GmbH Compound, method for preparing the compound, semiconducting material, organic electronic device, and display device

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6812024B2 (en) * 1987-03-16 2004-11-02 Mcgready Roland Keith Anti-paratopic antibody as an immunogen
US5245015A (en) * 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
AU1538392A (en) 1991-03-11 1992-10-06 Idec Pharmaceuticals Corporation Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations
EP0671920B1 (en) * 1992-03-09 2003-12-10 San Diego Regional Cancer Center An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US6057421A (en) * 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
CN101088561A (zh) 1998-07-21 2007-12-19 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
AU2002243259B2 (en) 2000-12-01 2008-02-07 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US6964199B2 (en) * 2001-11-02 2005-11-15 Cantocor, Inc. Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
US7625566B2 (en) * 2002-01-17 2009-12-01 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic monoclonal antibody reactive with HIV neutralizing antibody 2F5
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
EP2522678A1 (en) * 2006-05-15 2012-11-14 Sea Lane Biotechnologies, LLC Neutralizing antibodies to influenza viruses
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
KR20090059080A (ko) 2006-09-15 2009-06-10 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
JP2010538667A (ja) 2007-09-20 2010-12-16 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 新規オリゴクローナル抗体の製造方法
ITTO20080204A1 (it) * 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EA029198B1 (ru) 2010-03-26 2018-02-28 Помона Ричерка С.Р.Л. Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294084B1 (en) 2008-05-27 2015-09-09 Pomona Ricerca S.r.l. Monoclonal antibodies having homosubtype cross -neutralization properties against influenza a viruses subtype h1

Also Published As

Publication number Publication date
US9587011B2 (en) 2017-03-07
CN102037013B (zh) 2015-01-28
US9200063B2 (en) 2015-12-01
EA201071087A1 (ru) 2011-04-29
US20160200801A1 (en) 2016-07-14
US20110014187A1 (en) 2011-01-20
HUE025329T2 (en) 2016-02-29
CN102037013A (zh) 2011-04-27
DK2274335T3 (en) 2015-08-17
KR101605573B1 (ko) 2016-03-22
SG188890A1 (en) 2013-04-30
BRPI0909123A2 (pt) 2019-02-26
ES2544968T3 (es) 2015-09-07
BRPI0909123B8 (pt) 2021-06-01
US9598482B2 (en) 2017-03-21
EP2274335A1 (en) 2011-01-19
AU2009227567B2 (en) 2014-06-26
US20160060325A1 (en) 2016-03-03
EP2274335B8 (en) 2015-06-17
KR20100126810A (ko) 2010-12-02
BRPI0909123B1 (pt) 2020-12-01
JP5542118B2 (ja) 2014-07-09
ES2544968T5 (es) 2022-11-22
CA2718923C (en) 2020-07-07
WO2009115972A1 (en) 2009-09-24
EP2274335B1 (en) 2015-05-13
MX2010010120A (es) 2010-12-02
IL208210A0 (en) 2010-12-30
AU2009227567A1 (en) 2009-09-24
EP2274335B2 (en) 2022-07-27
ZA201006934B (en) 2011-12-28
MY157359A (en) 2016-05-31
EA027069B1 (ru) 2017-06-30
PL2274335T3 (pl) 2015-10-30
CA2718923A1 (en) 2009-09-24
JP2011517403A (ja) 2011-06-09
NZ588238A (en) 2012-08-31
PT2274335E (pt) 2015-09-18

Similar Documents

Publication Publication Date Title
ITTO20080204A1 (it) Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
HUS2300021I1 (hu) Anti-IL-36R antitestek
DK2954779T3 (da) Mus, der frembringer tungkædeantistoffer
DK2847231T3 (da) Multispecifikke monoklonale antistoffer
HRP20160484T1 (hr) Životinje koje izražavaju antitijela sa zajedničkim lakim lancem
EP2790756A4 (en) CAP ARRANGEMENT
SMT201700083B (it) Anticorpi monoclonali
EP2727287A4 (en) TRANSPARENT FALLING-UP
BR112012004387A2 (pt) anticorpos anticinas que se l igam a múltiplas quimiocinas cc.
HUE056313T2 (hu) Anti-DLL3 antitest
HUE054257T2 (hu) Könnyen izolálható, natív immunglobulin felépítésû bispecifikus antitestek
DK3323830T3 (da) Anti-gd2 antibodies
BR112013019035A2 (pt) reator.
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
IL229096A0 (en) Nasal rinse tip
LT2906597T (lt) Antikūnai, atpažįstantys beta amiloidą
CO6791565A2 (es) Anticuerpos anti-notch1
EP2755688A4 (en) HUMANIZED ANTIBODIES AGAINST INKT
DK3202789T3 (da) Anti-vla-4-antistoffer
CO6841994A2 (es) Anticuerpos
EP2595473A4 (en) TRANSGENIC PLANTS FOR THE EXPRESSION OF A VIRAL ANTIPILY PROTEIN
EP2854851A4 (en) Methods related to trastuzumab
IT1403438B1 (it) Rivestimento del manubrio.
EP2683601A4 (en) CHILDREN'S CAR WITH ELLIPTIC ARRANGEMENT
IT1401589B1 (it) Zeoliti ad azione neuroprotettiva.